Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STC007 (bupivacaine liposome)
- Development stage
- Phase 2
- Lead developer
- Chengdu Nuohe Shengtai Biotechnology
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Infiltration
01
Overview
STC007 is a long-acting local anesthetic formulation consisting of bupivacaine encapsulated in multivesicular liposomes. Developed by Chengdu Novo-Shengtai Biotechnology, it is designed to provide extended postoperative analgesia for up to 72 hours following surgical procedures. The liposomal delivery system allows for the slow, sustained release of bupivacaine into the surgical site, reducing the need for systemic opioids. Bupivacaine acts by binding to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing the generation and conduction of nerve impulses. STC007 is currently being evaluated in clinical trials for the management of moderate to severe pain following abdominal surgery and other surgical procedures.
- Other names
- bupivacaine liposome injectionbupivacaine multivesicular liposome injection
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on STC007 (bupivacaine liposome).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STC007 (bupivacaine liposome).